- Home
- SLN vs BYM Comparison
SLN vs BYM Comparison
Compare SLN & BYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- BYM
- Stock Information
- Founded
- SLN 1994
- BYM 2002
- Country
- SLN United Kingdom
- BYM United States
- Employees
- SLN N/A
- BYM N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- BYM Investment Managers
- Sector
- SLN Health Care
- BYM Finance
- Exchange
- SLN Nasdaq
- BYM Nasdaq
- Market Cap
- SLN 345.3M
- BYM 285.7M
- IPO Year
- SLN N/A
- BYM N/A
- Fundamental
- Price
- SLN $6.24
- BYM $10.98
- Analyst Decision
- SLN Buy
- BYM
- Analyst Count
- SLN 6
- BYM 0
- Target Price
- SLN $39.67
- BYM N/A
- AVG Volume (30 Days)
- SLN 213.8K
- BYM 60.2K
- Earning Date
- SLN 11-07-2025
- BYM 01-01-0001
- Dividend Yield
- SLN N/A
- BYM 4.49%
- EPS Growth
- SLN N/A
- BYM N/A
- EPS
- SLN N/A
- BYM N/A
- Revenue
- SLN $27,169,000.00
- BYM N/A
- Revenue This Year
- SLN N/A
- BYM N/A
- Revenue Next Year
- SLN N/A
- BYM N/A
- P/E Ratio
- SLN N/A
- BYM N/A
- Revenue Growth
- SLN 22.28
- BYM N/A
- 52 Week Low
- SLN $1.97
- BYM $9.30
- 52 Week High
- SLN $18.24
- BYM $11.77
- Technical
- Relative Strength Index (RSI)
- SLN 46.82
- BYM 50.83
- Support Level
- SLN $7.06
- BYM $10.89
- Resistance Level
- SLN $7.39
- BYM $11.03
- Average True Range (ATR)
- SLN 0.58
- BYM 0.08
- MACD
- SLN -0.12
- BYM -0.01
- Stochastic Oscillator
- SLN 21.87
- BYM 45.00
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.